Gallant CRT-D Adverse Events: FDA MAUDE Data

ABBOTT (ST. JUDE MEDICAL) · CRT-Defibrillator (CRT-D) · First cleared May 2024 · 5 device variants grouped

Total Reports

9,178

Reports (30d)

172

Active Signals

2

Open Recalls

2

Monthly Report Volume
Event Type Breakdown

Most commonly reported problems

1

Remote Monitoring Oversensing Episodes

merlin net, net review, presented remotely, net, remotely merlin

66

reports

2

Post-Paced T-Wave Oversensing Observed

oversensing, contacted recommended, implantable cardioverter, observed device, support contacted

57

reports

3

Remote Follow-Up Oversensing Observed

observed device, remote follow, technical support, device technical, stable continue

21

reports

4

Inappropriate Shock Delivered by ICD

implantable cardioverter, icd, shock, cardioverter defibrillator, defibrillator icd

21

reports

5

Post-Paced T-Wave Oversensing Reported

patient consequences, consequences reported, sensing, programming changes, patient implantable

18

reports

6

Dislodged Left Ventricular Lead

left, lead, replaced, left ventricular, ventricular lead

18

reports

Problem groupings are generated by Claripulse from report narrative text. They summarize what reporters wrote, not adjudicated root cause.

Active safety signals

Increasing trendcriticalVolume spikehigh

FDA recalls for this device

Class II

Aug 16, 2023 · Open, Classified

Due to Bluetooth malfunction on a subset of Implantable Cardioverter Defibrillator (ICD) and Cardia Resynchronization Therapy Defibrillator *CRT-D) devices that were manufactured prior to April 2022 as a result of crystal component issue within the Bluetooth Low Energy (BLE) circuit. This results in the device entering an inductive telemetry only mode with loss of Bluetooth communication. In some instances, thought BLE communication is unavailable, the circuit may remain in a state which draws excessive power affecting battery longevity.

Class II

Mar 10, 2022 · Open, Classified

Due to a programmer software anomaly under very specific circumstance when executing a pacing capture Decrement Test in-clinic on implantable cardioverter and cardiac resynchronization therapy defibrillator devices, the programmer may continue to execute the Decrement Test instead of terminating the test and restoring the permanent programmed pacing parameters.

Want automated safety signal detection?

Claripulse monitors these devices weekly and detects anomalies using 6 statistical methods — spike, trend, changepoint, peer-outlier, and more. 2 active signals detected right now.

Get Early Access
Disclaimer: This system analyzes publicly available FDA MAUDE data. It does NOT provide medical advice. MAUDE data is de-identified. Do not attempt re-identification. Report counts may differ from the FDA's MAUDE search due to processing cadence and deduplication. Data is updated weekly.